doValue (DOV) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
1 Nov, 2026Executive summary
FY23 gross revenue was €485.7m, down 13.0% YoY; adjusted EBITDA was €178.4m, down 11.5% reported and 4.1% excluding Sareb.
Year-end managed GBV was €116.4bn, down 3.4% YoY; €10.6bn of new GBV was secured or onboarded.
Leverage was 2.7x, within the 2.0–3.0x target range; the 2024–2026 business plan was scheduled for presentation on 21 March 2024.
Financial highlights
Net revenue was €443.2m, down 11.4%; excluding Sareb, gross and net revenue fell 4.6% and 4.4%, respectively.
Q4 adjusted EBITDA was €63m, up 26.6% YoY, with a 43.2% margin; Q4 gross revenue rose 13.5% to €151m.
Attributable net loss was €18.9m; attributable net income excluding non-recurring items was €2.7m, versus €50.6m in FY22.
Collections totaled €4.9bn, down 10.0% reported and up 5.1% excluding Sareb; collection rate increased to 4.6% from 4.1%.
Operating cash flow was €79.4m and capex €21.3m; free cash flow before dividends and equity investments was €28.5m.
Outlook and guidance
2024 was positioned as a transformation year focused on cost rationalization and investment to prepare for growth in 2025–2026; full savings effects were not expected in H1.
A potential Southern European servicing-mandate pipeline of €40bn was identified over the next 18 months, including secondary transactions.
Primary deal completions could slow as banks’ sound balance sheets reduce urgency, challenging a return to growth in 2024.
The 2024–2026 plan, including dividend policy, was scheduled for presentation at the 21 March 2024 Capital Markets Day.
Latest events from doValue
- Digital growth and AI efficiencies underpin the €330m–€350m EBITDA target for 2029.DOV
CMD 2026 - Q2 revenue up 30% YoY to €181m, digital and coeo drive growth, EBITDA guidance reaffirmed.DOV
Q2 2026 - High-growth, asset-light platform with strong cash generation and expanding digital services.DOV
Investor presentation - Q1 EBITDA ex NRIs €35M, revenue down 14.9% YoY, leverage 2.3x, coeo acquisition completed.DOV
Q1 2026 - EBITDA ex-NRI up 32% YoY, net income ex-NRI tripled, and leverage improved to 2.0x.DOV
Q4 2025 - Record revenue and EBITDA growth, strong cash flow, and digital expansion via coeo acquisition.DOV
Q2 2025 - Achieved €8bn new GBV, confirmed guidance, and advanced the Gardant acquisition.DOV
Q3 2024 - EBITDA and revenues declined, but net profit rose and Gardant acquisition advanced.DOV
Q2 2024 - Revenues up 46% YoY, EBITDA ex-NRI doubled, and new business GBV exceeded targets.DOV
Q1 2025